CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:T Lymphocyte and CAR-T Cell-Derived Extracellular Vesicles and Their Applications in Cancer Therapy.
T Lymphocyte and CAR-T Cell-Derived Extracellular Vesicles and Their Applications in Cancer Therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
细胞外囊泡(EV)是一类高度多样化的细胞来源囊泡,几乎可由所有类型的活细胞释放。EV参与近距离和全身性的细胞间交换,因为它们诱导信号并将其货物(蛋白质、脂质、miRNAs)传递给其他细胞,随后在靶细胞中引发多种生物学反应。然而,细胞表面受体诱导的EV释放仅限于免疫系统细胞,包括T淋巴细胞。T淋巴细胞的T细胞受体激活可诱导EV分泌,这些EV含有针对抗原的T细胞受体以及多种生物活性分子,包括促凋亡蛋白。这些EV对抗原携带细胞具有特异性,使其成为无细胞、EV依赖性癌症治疗的理想候选者。在这篇综述中,我们探讨了T淋巴细胞和CAR-T 细胞产生EV的过程以及这些EV的一些潜在治疗策略。
Extracellular vesicles (EV) are a very diverse group of cell-derived vesicles released by almost all kind of living cells. EV are involved in intercellular exchange, both nearby and systemically, since they induce signals and transmit their cargo (proteins, lipids, miRNAs) to other cells, which subsequently trigger a wide variety of biological responses in the target cells.
However, cell surface receptor-induced EV release is limited to cells from the immune system, including T lymphocytes. T cell receptor activation of T lymphocytes induces secretion of EV containing T cell receptors for antigen and several bioactive molecules, including proapoptotic proteins. These EV are specific for antigen-bearing cells, which make them ideal candidates for a cell-free, EV-dependent cancer therapy. In this review we examine the generation of EV by T lymphocytes and CAR-T cells and some potential therapeutic approaches of these EV.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。